A Look At Corcept Therapeutics (CORT) Valuation After FDA Complete Response Letter For Relacorilant

Simply Wall St

Thu, February 19, 2026 at 5:21 PM GMT+9 3 min read

In this article:

CORT

+0.48%

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

Why Corcept Therapeutics (CORT) Is Back in Focus

The U.S. FDA’s Complete Response Letter for Corcept Therapeutics (CORT) relacorilant program, which calls for more evidence and pushes potential market entry back by about three years, has become the key driver of recent stock sentiment.

See our latest analysis for Corcept Therapeutics.

At a share price of $39.82, Corcept’s 30 day share price return of 14.66% suggests a partial rebound after the sharp 46.94% 90 day share price decline that followed the FDA letter. The 1 year total shareholder return of 45.85% and 3 year total shareholder return of 82.33% show how much longer term holders have still seen value creation despite recent volatility.

If regulatory headlines around Corcept have you reassessing your biotech exposure, you may want to broaden your search with our screener of 25 healthcare AI stocks as potential next ideas to research.

With Corcept trading at $39.82 against an $84.00 analyst target and an indicated intrinsic discount of 87.88%, you have to ask yourself: is this pricing error, or is the market already discounting all the future growth potential?

Most Popular Narrative: 37.3% Undervalued

According to the most followed narrative, Corcept Therapeutics’ fair value sits above its last close of $39.82, setting up a clear valuation gap for investors to examine more closely.

Ottima azienda solida finanziariamente senza debiti a lungo e breve termine. Il FcF tende a diminuire nel tempo mentre aumentano i compensi per i vari membri del board che hanno uno skill in the game moderato. Calcolando il DCF , con un approccio un po ottimistico, quindi , valutando la crescita del fcf al 10% per i primi 5 annni e al 7% dal 6 al 10, calcolando un tasso di sconto al 12% e una crescita del 3% annuo (valore in linea con l aumento medio del pil Usa) il mio fair value è di circa 33 euro al quale sottraggo un MoS del 30% , quindi ho impostato l acquisto a 23 euro circa. Anche il P/E di 31 mi da un’ indicazione del genere, Quindi attualmente è sopravvalutata.

Read the complete narrative.

Curious how Giuca’s narrative gets from Corcept’s current profitability to a higher fair value? The story leans heavily on sustained revenue momentum and firm margins, blended with a discount rate that keeps future cash flows surprisingly robust. The real twist sits in the profit assumptions and the earnings multiple baked into that target. If you want to see exactly which levers are doing the heavy lifting, the full narrative lays it all out.

Story continues  

Result: Fair Value of $63.53 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this story can break if regulatory timelines slip again or if profitability metrics, such as margins implied by the P/E of 31, compress materially.

Find out about the key risks to this Corcept Therapeutics narrative.

Next Steps

With sentiment clearly divided, it may be useful to review the same numbers yourself and decide how much risk and potential you really see, starting with 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Corcept has sharpened your thinking, do not stop here. The next strong move in your portfolio may come from widening your search beyond a single stock.

Target resilient cash generators by scanning our 53 high quality undervalued stocks that pair compressed prices with stronger fundamentals than the headline suggests.

Strengthen your income stream by reviewing 13 dividend fortresses, a set of companies offering yields above 5% with a focus on staying power.

Build a sturdier core for your portfolio by checking solid balance sheet and fundamentals stocks screener (43 results), highlighting businesses with robust financial footing to support future decisions.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include CORT.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info